Lupin unveils asthma drug Zileuton ER Tablets
The tablet is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
Mumbai, Baltimore: Pharma major Lupin Limited has announced the launch of Zileuton Extended-Release Tablets, 600 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
The product would be manufactured at Lupin's Nagpur facility, India.
Zileuton Extended-Release Tablets, 600 mg, is the generic equivalent of Zyflo CR® Extended-Release Tablets, 600 mg, of Chiesi USA, Inc. and is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
Zileuton Extended-Release Tablets (RLD: Zyflo CR®) had an annual sales of approximately USD 40 million in the U.S. (IQVIA MAT June 2020).
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.